Denise D Correa1, Lisa M Hess. 1. Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. corread@mskcc.org
Abstract
OBJECTIVES: As advances in treatment have prolonged survival for many patients with ovarian cancer, there has been growing interest in assessing the adverse effects of disease and treatment. The aim of this study was to review the literature on cognitive function and quality of life (QOL) in this population. METHODS: A review of published studies including formal assessment of neurocognitive functions and self-reported domains of quality of life, with an emphasis on cognitive function, was performed. RESULTS: The small number of studies including formal evaluations of neurocognitive function suggests that many ovarian cancer patients experience cognitive difficulties associated with their disease and treatment. Several studies described declines in self-reported cognitive function that may impact QOL, but the results were not consistent across studies. CONCLUSIONS: Adequately powered longitudinal studies including formal neurocognitive and QOL assessments are needed to advance our understanding of the incidence of cognitive dysfunction and its impact on functional ability and QOL in ovarian cancer patients. These research efforts may ultimately contribute to treatment decision-making through the identification of vulnerable patients, and to the development of appropriate intervention strategies to improve cognitive function and QOL.
OBJECTIVES: As advances in treatment have prolonged survival for many patients with ovarian cancer, there has been growing interest in assessing the adverse effects of disease and treatment. The aim of this study was to review the literature on cognitive function and quality of life (QOL) in this population. METHODS: A review of published studies including formal assessment of neurocognitive functions and self-reported domains of quality of life, with an emphasis on cognitive function, was performed. RESULTS: The small number of studies including formal evaluations of neurocognitive function suggests that many ovarian cancerpatients experience cognitive difficulties associated with their disease and treatment. Several studies described declines in self-reported cognitive function that may impact QOL, but the results were not consistent across studies. CONCLUSIONS: Adequately powered longitudinal studies including formal neurocognitive and QOL assessments are needed to advance our understanding of the incidence of cognitive dysfunction and its impact on functional ability and QOL in ovarian cancerpatients. These research efforts may ultimately contribute to treatment decision-making through the identification of vulnerable patients, and to the development of appropriate intervention strategies to improve cognitive function and QOL.
Authors: Miles Berger; Jacob W Nadler; Jeffrey Browndyke; Niccolo Terrando; Vikram Ponnusamy; Harvey Jay Cohen; Heather E Whitson; Joseph P Mathew Journal: Anesthesiol Clin Date: 2015-07-16
Authors: Kevin T Liou; James C Root; Sheila N Garland; Jamie Green; Yuelin Li; Q Susan Li; Philip W Kantoff; Tim A Ahles; Jun J Mao Journal: Cancer Date: 2020-04-22 Impact factor: 6.860
Authors: Jennifer R Klemp; Jamie S Myers; Carol J Fabian; Bruce F Kimler; Qamar J Khan; Susan M Sereika; Annette L Stanton Journal: Support Care Cancer Date: 2017-08-28 Impact factor: 3.603
Authors: Naomi Lomeli; Kaijun Di; Jennifer Czerniawski; John F Guzowski; Daniela A Bota Journal: Free Radic Biol Med Date: 2016-11-28 Impact factor: 7.376
Authors: Nadia Miladi; Richi Dossa; Maman Joyce Dogba; Marie Immacula Fabienne Cléophat-Jolicoeur; Bruno Gagnon Journal: Support Care Cancer Date: 2019-06-28 Impact factor: 3.603
Authors: Shannon N Westin; Charlotte C Sun; Celestine S Tung; Robin A Lacour; Larissa A Meyer; Diana L Urbauer; Michael M Frumovitz; Karen H Lu; Diane C Bodurka Journal: J Cancer Surviv Date: 2015-08-06 Impact factor: 4.442
Authors: Lisa M Hess; Helen Q Huang; Alexandra L Hanlon; William R Robinson; Rhonda Johnson; Setsuko K Chambers; Robert S Mannel; Larry Puls; Susan A Davidson; Michael Method; Shashikant Lele; Laura Havrilesky; Tina Nelson; David S Alberts Journal: Gynecol Oncol Date: 2015-10-09 Impact factor: 5.482